Printer Friendly

THE JOURNAL OF CLINICAL MICROBIOLOGY REPORTS THAT A NEW FDA-APPROVED AIDS TEST WILL IMPROVE SPECIFICITY OF HIV CONFIRMATORY TESTING

 THE JOURNAL OF CLINICAL MICROBIOLOGY REPORTS THAT A NEW FDA-APPROVED
 AIDS TEST WILL IMPROVE SPECIFICITY OF HIV CONFIRMATORY TESTING
 HOUSTON, Aug. 17 /PRNewswire/ -- TeleConcepts Corporation (AMEX: TCC) today announced that uncertainty in confirmatory testing for the human immunodeficiency virus (the second stage of testing for HIV antibodies following initial blood bank screening procedures), could be virtually eliminated by the recently licensed Fluorognost HIV-1 IFA AIDS test, as reported in a recent study by American Red Cross scientists. This FDA-approved test is being distributed by Viral Testing Systems Corporation. Thermascan, Inc. (OTC: THEM), which will merge with TeleConcepts later this month to form Viral Testing Systems Corporation, has exclusive North American rights to market and sell Fluorognost.
 A paper published in the September 1992 issue of the Journal of Clinical Microbiology focuses on blood samples from former blood donors for which the conventional HIV-1 confirmatory test procedures (Western blot) failed to provide conclusive results. Such "indeterminate" confirmatory test results may or may not be indicative of an early state of infection with the immunodeficiency virus, which causes AIDS. Western blot results may also vary depending on what interpretive criteria are used.
 Fluorognost HIV-1 IFA was able to accurately resolve the status of 53 blood donor samples found to be "indeterminate" by Western blot testing. Four of these donors were found to be HIV infected by the 90- minute Fluorognost assay, while 49 tested negative. These results were in complete accordance with those obtained with the radioimmunoprecipitation assay (RIPA), a complex procedure available only in laboratories.
 Although blood units with reactive screening test results are never released for transfusion, improved accuracy of the confirmatory procedure will help to prevent much anxiety on the part of individuals who are provided with uncertain HIV-related test results. In addition, individuals with negative confirmatory test results. In addition, individuals with negative confirmatory test results may be eligible for re-entry into the donor pool upon additional testing following FDA approved procedures.
 In contrast, individuals with clear evidence of infection can then be accurately notified of their infection and educated about precautions that must be taken to prevent the transmission of HIV infection to their sexual partners.
 TeleConcepts currently designs and markets telephones and telephone devices for residential and commercial use. Thermascan has exclusive North American rights to market and sell Fluorognost and a panel of 14 all-human monoclonal antibody reagents which are directed against the HIV-1 virus. After the merger, the medical diagnostics and biotech business will continue in a separate public company, Viral Testing Systems Corporation, and the telephone business will continue as TeleConcepts, Inc. As previously reported, TeleConcepts does not currently meet the requirements for continued listing on the American Stock Exchange, and there is no assurance that its listing will continue. Also, there can be no assurance that Fluorognost can be successfully marketed in the United States.
 -0- 8/17/92
 /CONTACT: Holly Vaughan of TeleConcepts, 713-228-4633, or Elizabeth Hall of American Red Cross, 202-639-3122/
 (TCC THEM) CO: TeleConcepts Corporation; Viral Testing Systems Corporation ST: Texas IN: MTC SU:


TS-LR -- NY011 -- 0498 08/17/92 12:08 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 17, 1992
Words:514
Previous Article:SANDOZ NAMES RONALD SCHMID EXECUTIVE DIRECTOR, EXTERNAL AFFAIRS
Next Article:NABI AWARDED $7 MILLION NAVY TESTING CONTRACT
Topics:


Related Articles
TELECONCEPTS SAYS AIDS TEST MAY IDENTIFY NEW HIV STRAIN
THERMASCAN STATEMENT ON UNRESOLVED HIV-1 ANTIBODY STATUS
NEW FDA LICENSED AIDS TEST WILL IMPROVE SPECIFICITY OF HIV CONFIRMATORY TESTING FOR THE BLOOD SUPPLY
FDA-APPROVED 10-MINUTE HIV TEST AVAILABLE IN MICHIGAN
THERMASCAN PREPARES TO FILE IND WITH FDA FOR FLUOROGNOST HIV-2 IFA
VIROLOGY TESTING SCIENCES, INC. ANNOUNCES NEW HIV-2 CONFIRMATION AND SCREENING TEST
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION ANNOUNCES INTRODUCTION OF 10-MINUTE SUDS(R) HIV-1+2 ANTIBODY TEST TO INTERNATIONAL MARKETS
EPITOPE RECEIVES FDA APPROVAL TO MARKET ORASURE DEVICE
EPITOPE REPORTS SECOND QUARTER OPERATING RESULTS
EPITOPE SUBMITS APPLICATION FOR FDA APPROVAL OF ORAL HIV CONFIRMATORY TEST

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters